Janssen-Cilag International NV Withdraws Its Marketing Authorisation Application For Comfyde (Carisbamate), Europe
Janssen-Cilag International NV Withdraws Its Marketing Authorisation Application For Comfyde (Carisbamate), Europe The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for a centralised marketing authorisation for the medicine Comfyde (carisbamate) 100mg, 200mg, 400mg and 600mg film-coated tablets. This medicine was intended to be used …